Records 1 - 11
| Association between CYP2A13 polymorphisms and lung cancer: A protocol for systematic review and meta-analysis.
Medicine 2020 Dec 99 (50): e23289.
Ma Long, Jin Gang, Yang Yi, Pang Yao, Wang Wenhao, Zhang Hongyi, Liu Jiawei, Wu Peng, Wang Zequan, Wang Kui, Chang Ruitong, Li Jialong, Zhu Zijia
| HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers.
Thoracic cancer 2019 Feb .
Hua Feng, Guo Yonglu, Sun Qiang, Yang Leizhou, Gao Fa
| Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2015 May 29 (5): 1986-98.
Xiang Chan, Wang Jiucun, Kou Xiaochen, Chen Xiabin, Qin Zhaoyu, Jiang Yan, Sun Chang, Xu Jibin, Tan Wen, Jin Li, Lin Dongxin, He Fuchu, Wang Haiji
| Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes.
Clinica chimica acta; international journal of clinical chemistry 2015 Feb 441 71-4.
Shimizu Makiko, Sawaya Ren, Kishimoto Izumi, Yamazaki Hiros
| Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
Current drug metabolism 2015 16 (10): 850-63.
He Xin, Feng Sh
| Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma.
Cancer epidemiology 2013 Oct 37 (5): 5.
Chiang HC, Lee H, Chao HR, Chiou YH, Tsou TC
| Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan.
Drug metabolism and pharmacokinetics 2011 26 (5): 516-22.
Tamaki Yuichiro, Arai Tomio, Sugimura Haruhiko, Sasaki Takamitsu, Honda Masashi, Muroi Yuka, Matsubara Yoichi, Kanno Shuichi, Ishikawa Masaaki, Hirasawa Noriyasu, Hiratsuka Masahi
| CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences.
Carcinogenesis 2009 Jul 30 (7): 1161-9.
Timofeeva Maria N, Kropp Silke, Sauter Wiebke, Beckmann Lars, Rosenberger Albert, Illig Thomas, Jäger Birgit, Mittelstrass Kirstin, Dienemann Hendrik, , Bartsch Helmut, Bickeböller Heike, Chang-Claude Jenny C, Risch Angela, Wichmann Heinz-Eri
| Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility.
Biochemical and biophysical research communications 2004 Apr 317 (2): 662-9.
Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenée S, Hamdan R, Lhermitte M, Lafitte JJ, Libersa C, Colombel JF, Stücker I, Broly F
| Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Cancer research 2003 Nov 63 (22): 8057-61.
Wang Haijian, Tan Wen, Hao Bingtao, Miao Xiaoping, Zhou Gangqiao, He Fuchu, Lin Dongx
| Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Toxicology 2001 Nov 168 (3): 259-68.
Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride C M, Bepler